Funding Fuels a New Era in Clinical Research

Biorce, a healthtech startup based in Barcelona, has raised €5 million in a new seed funding round led by Norrsken VC. Founded in 2024 by Pedro Coelho, Biorce is tackling one of the most persistent challenges in medicine: the inefficiencies that plague clinical trials. With this funding, Biorce aims to expand its flagship AI platform, Jarvis, designed to transform the way trials are designed, executed, and optimized.

Addressing Critical Inefficiencies in Clinical Trials

Clinical trials are notorious for being slow, expensive, and fraught with delays. Around 70% of trials face timeline extensions, while up to 60% undergo costly protocol amendments. Biorce’s Jarvis platform directly addresses these issues by aggregating data from over half a million enriched and annotated clinical studies. Its AI-driven assistant supports smarter protocol design, optimized site selection, more accurate patient recruitment, and real-time feasibility analysis. By streamlining these complex processes, Biorce helps researchers accelerate timelines and reduce unnecessary costs without compromising safety.

What sets Biorce apart isn’t just its ability to fix obvious inefficiencies; it’s the way the team has focused on deeper, unspoken obstacles in trial workflows. Rather than offering only incremental improvements, Biorce set out to solve what could be called the system’s “dark matter” - the silent, persistent bottlenecks that slow progress and often go unnoticed. By designing Jarvis to address protocol complexity and feasibility opacity, the team effectively turned optional analytics into essential infrastructure. 

For founders building AI products, this is a powerful lesson: truly impactful innovation uncovers and resolves latent, unarticulated pain points that customers might not fully recognize until they’re eliminated. This approach transforms an auxiliary feature into a core operational necessity, embedding the technology deeply into daily workflows and making it indispensable.

Strong Investor Confidence Validates the Vision

The new investment from Norrsken VC and other top-tier backers signals robust confidence in Biorce’s mission and long-term growth potential. These investors believe Biorce has the power to significantly reduce trial costs, improve patient recruitment outcomes, and accelerate the delivery of life-saving therapies to market.

The latest funding round follows a €3.5 million raise in late 2024, which helped Biorce refine its core platform and expand its dataset. Now, with fresh capital, the company plans to double down on growth and expand internationally.

Scaling Up: A Clear Roadmap for Global Impact

Biorce intends to use the new funds to further develop Jarvis, strengthen its engineering and clinical affairs teams, and establish a stronger presence in the U.S. and broader European markets. The company also plans to increase integrations with pharmaceutical companies, contract research organizations (CROs), and academic research centers.

By providing comprehensive support throughout the entire trial lifecycle - from protocol design to real-time feasibility - Jarvis offers a level of insight and adaptability that traditional systems simply can’t match. This end-to-end approach positions Biorce to become a critical partner in the future of clinical research.

Competitive Differentiation: A Unified Platform

Unlike most solutions that target individual fragments of the trial process, Jarvis stands out by offering a unified, multimodal approach. Its ability to combine data-driven feasibility analysis, protocol optimization, and patient recruitment in a single platform makes it especially attractive to sponsors and CROs looking to consolidate their tech stacks and improve efficiency.

Biorce’s deep dataset - comprising over 530,000 studies - enables it to deliver insights grounded in real-world evidence rather than theoretical models alone. This gives trial designers a higher level of confidence when making decisions that affect both patient safety and study timelines.

Broad Applicability Across Therapeutic Areas

While initially focused on more traditional therapeutic areas, Biorce’s platform is designed to adapt across a wide range of clinical specialties, including oncology, neurology, infectious diseases, and rare diseases. By remaining protocol-agnostic, Jarvis is able to continuously learn and improve as more trials are run on the platform, generating a self-reinforcing cycle of better data and smarter recommendations.

This scalability and adaptability provide Biorce with a significant long-term growth opportunity and position the company as a potential leader in the global clinical trials market.

Setting a New Standard for Future Clinical Trials

Biorce’s latest funding round marks a crucial milestone in its mission to make clinical research faster, more efficient, and ultimately more patient-centered. By leveraging AI and data science to attack both visible inefficiencies and the hidden frictions that quietly undermine trial success, Biorce is redefining what’s possible in clinical operations.

With strong investor backing, a robust technological foundation, and a clear strategic vision, Biorce is well-positioned to become a transformative force in the biopharma industry. The company’s ability to merge domain expertise with advanced AI illustrates a powerful path forward for other founders aiming to tackle complex, high-stakes problems in healthcare and beyond.